Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 11 studies | 31% ± 12% | |
connective tissue cell | 7 studies | 36% ± 4% | |
astrocyte | 7 studies | 26% ± 8% | |
epithelial cell | 7 studies | 33% ± 14% | |
mesothelial cell | 7 studies | 46% ± 14% | |
basal cell | 7 studies | 24% ± 10% | |
oligodendrocyte | 6 studies | 23% ± 7% | |
smooth muscle cell | 6 studies | 24% ± 3% | |
myofibroblast cell | 5 studies | 25% ± 5% | |
abnormal cell | 5 studies | 20% ± 6% | |
pericyte | 5 studies | 19% ± 4% | |
progenitor cell | 4 studies | 26% ± 4% | |
ciliated cell | 4 studies | 22% ± 8% | |
adventitial cell | 4 studies | 23% ± 4% | |
oligodendrocyte precursor cell | 4 studies | 27% ± 8% | |
hematopoietic precursor cell | 3 studies | 24% ± 2% | |
kidney distal convoluted tubule epithelial cell | 3 studies | 52% ± 19% | |
epithelial cell of proximal tubule | 3 studies | 32% ± 19% | |
neural crest cell | 3 studies | 38% ± 14% | |
myoepithelial cell | 3 studies | 23% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 99% | 6702.20 | 2613 / 2642 | 100% | 96.97 | 703 / 705 |
prostate | 99% | 5105.19 | 243 / 245 | 97% | 55.56 | 489 / 502 |
ovary | 99% | 4012.63 | 179 / 180 | 96% | 48.18 | 413 / 430 |
uterus | 93% | 2943.83 | 158 / 170 | 92% | 62.33 | 422 / 459 |
bladder | 100% | 3202.14 | 21 / 21 | 79% | 38.97 | 396 / 504 |
skin | 100% | 8405.31 | 1806 / 1809 | 75% | 70.87 | 355 / 472 |
thymus | 86% | 2425.98 | 564 / 653 | 84% | 29.51 | 510 / 605 |
esophagus | 93% | 2906.68 | 1339 / 1445 | 70% | 26.83 | 128 / 183 |
liver | 99% | 5286.00 | 223 / 226 | 62% | 22.87 | 252 / 406 |
pancreas | 100% | 4356.15 | 328 / 328 | 58% | 13.86 | 103 / 178 |
breast | 84% | 2324.29 | 387 / 459 | 66% | 33.13 | 739 / 1118 |
stomach | 96% | 2768.19 | 343 / 359 | 48% | 16.92 | 137 / 286 |
kidney | 98% | 2852.94 | 87 / 89 | 39% | 10.08 | 350 / 901 |
intestine | 73% | 1765.69 | 709 / 966 | 59% | 20.58 | 312 / 527 |
lung | 63% | 1546.94 | 365 / 578 | 57% | 25.21 | 662 / 1155 |
blood vessel | 99% | 4273.77 | 1315 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 91% | 44.52 | 41 / 45 |
adipose | 79% | 2371.13 | 947 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 59% | 18.25 | 47 / 80 |
lymph node | 0% | 0 | 0 / 0 | 45% | 13.08 | 13 / 29 |
heart | 40% | 721.44 | 345 / 861 | 0% | 0 | 0 / 0 |
spleen | 20% | 276.46 | 49 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 20% | 758.86 | 183 / 929 | 0% | 0 | 0 / 0 |
adrenal gland | 3% | 33.62 | 7 / 258 | 8% | 1.96 | 18 / 230 |
muscle | 1% | 12.26 | 7 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0021782 | Biological process | glial cell development |
GO_0010468 | Biological process | regulation of gene expression |
GO_0070314 | Biological process | G1 to G0 transition |
GO_0021510 | Biological process | spinal cord development |
GO_0006544 | Biological process | glycine metabolic process |
GO_0031175 | Biological process | neuron projection development |
GO_0006566 | Biological process | threonine metabolic process |
GO_0006541 | Biological process | glutamine metabolic process |
GO_0019530 | Biological process | taurine metabolic process |
GO_0009448 | Biological process | gamma-aminobutyric acid metabolic process |
GO_0007420 | Biological process | brain development |
GO_0006564 | Biological process | L-serine biosynthetic process |
GO_0021915 | Biological process | neural tube development |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0004617 | Molecular function | phosphoglycerate dehydrogenase activity |
GO_0009055 | Molecular function | electron transfer activity |
GO_0051287 | Molecular function | NAD binding |
GO_0030060 | Molecular function | L-malate dehydrogenase (NAD+) activity |
Gene name | PHGDH |
Protein name | D-3-phosphoglycerate dehydrogenase (EC 1.1.1.95) Phosphoglycerate dehydrogenase D-3-phosphoglycerate dehydrogenase (3-PGDH) (EC 1.1.1.95) (2-oxoglutarate reductase) (EC 1.1.1.399) (Malate dehydrogenase) (EC 1.1.1.37) D-3-phosphoglycerate dehydrogenase |
Synonyms | PGDH3 |
Description | FUNCTION: Catalyzes the reversible oxidation of 3-phospho-D-glycerate to 3-phosphonooxypyruvate, the first step of the phosphorylated L-serine biosynthesis pathway. Also catalyzes the reversible oxidation of 2-hydroxyglutarate to 2-oxoglutarate and the reversible oxidation of (S)-malate to oxaloacetate. . |
Accessions | A0A286YEZ0 ENST00000641513.1 A0A286YF22 Q8N5M8 ENST00000641891.1 A0A286YFC8 A0A286YER3 ENST00000641213.1 ENST00000641247.1 ENST00000641074.1 A0A286YFK5 ENST00000641720.1 ENST00000642041.1 A0A286YF34 A0A286YFL2 A0A286YFA2 A0A286YFM8 A0A286YF78 O43175 ENST00000641811.1 ENST00000641371.1 ENST00000641272.1 ENST00000641023.2 ENST00000641115.1 ENST00000641375.1 ENST00000641491.1 ENST00000369409.9 ENST00000641947.1 ENST00000641587.1 ENST00000641597.1 A0A286YFE1 A0A286YFF3 A0A2C9F2M7 A0A286YFB2 ENST00000641756.1 ENST00000641570.1 ENST00000493622.5 |